Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.

Flachenecker P.

Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):15-9. doi: 10.1586/ern.13.1. Review.

PMID:
23369055
2.

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.

García-Merino A.

Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):9-13. doi: 10.1586/ern.13.4. Review.

PMID:
23369054
3.

Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.

Slof J, Gras A.

Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):439-41. doi: 10.1586/erp.12.40. Epub 2012 Jun 8.

PMID:
22681512
4.

Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.

Arroyo R, Vila C, Dechant KL.

J Comp Eff Res. 2014 Jul;3(4):435-44. doi: 10.2217/cer.14.30. Review.

PMID:
25275238
5.

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Pozzilli C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Review.

PMID:
24289844
6.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Syed YY, McKeage K, Scott LJ.

Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review.

PMID:
24671907
7.
8.

Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.

Slof J, Ruiz L, Vila C.

Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):379-91. doi: 10.1586/14737167.2015.1025759. Epub 2015 Mar 16.

PMID:
25771713
9.
10.

Multiple sclerosis spasticity daily management: retrospective data from Europe.

Berger T.

Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):3-7. doi: 10.1586/ern.13.3. Review.

PMID:
23369053
11.

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Oreja-Guevara C.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Review.

PMID:
22509985
12.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Sastre-Garriga J, Vila C, Clissold S, Montalban X.

Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Review.

PMID:
21456949
13.

Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionals.

Collongues N, Vermersch P.

Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):21-5. doi: 10.1586/ern.13.10. Review.

PMID:
23369056
14.

Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.

Lu L, Pearce H, Roome C, Shearer J, Lang IA, Stein K.

Pharmacoeconomics. 2012 Dec 1;30(12):1157-71. doi: 10.2165/11598470-000000000-00000. Erratum in: Pharmacoeconomics. 2015 Jun;33(6):611.

PMID:
23072659
15.

Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Foreword.

Trojano M.

Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):1. doi: 10.1586/ern.13.2. No abstract available.

PMID:
23369052
16.

Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.

Freidel M, Tiel-Wilck K, Schreiber H, Prechtl A, Essner U, Lang M.

Acta Neurol Scand. 2015 Jan;131(1):9-16. doi: 10.1111/ane.12287. Epub 2014 Sep 11.

PMID:
25208898
17.
18.

Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.

Flachenecker P, Henze T, Zettl UK.

Eur Neurol. 2014;72(1-2):95-102. doi: 10.1159/000360285. Epub 2014 Jun 18.

PMID:
24943098
19.

What place for ▾ cannabis extract in MS?

[No authors listed]

Drug Ther Bull. 2012 Dec;50(12):141-4. doi: 10.1136/dtb.2012.11.0150. Review.

PMID:
23241565
20.

Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.

Squintani G, Donato F, Turri M, Deotto L, Teatini F, Moretto G, Erro R.

J Neurol Sci. 2016 Nov 15;370:263-268. doi: 10.1016/j.jns.2016.09.054. Epub 2016 Sep 28.

PMID:
27772772

Supplemental Content

Support Center